Diagnostic Accuracy of Capillary Blood Glucometer Testing for Gestational Diabetes
DOI: https://doi.org/10.2147/DMSO.S389420
2022-12-14
Abstract:Héctor Gallardo-Rincón, 1, 2 Julieta Lomelin-Gascon, 2 Luis Alberto Martinez-Juarez, 2 Alejandra Montoya, 2 Janinne Ortega-Montiel, 2 Victoria Galicia-Hernandez, 2 Diego-Abelardo Álvarez-Hernández, 2 Rosangela Ávila-Domínguez, 2 Enrique Reyes-Muñoz, 3 Lucía Marcela Illescas-Correa, 4 Daniel Alberto Diaz Martinez, 5 Francisco Javier Magos Vázquez, 5 Edwin Oswaldo Vargas Ávila, 5 Alejandro Efraín Benitez-Herrera, 6 Diana Reyes-Gómez, 6 María Concepción Carmona-Ramos, 6 Laura Hernández-González, 6 Oscar Romero-Islas, 6 Ricardo Mújica-Rosales, 2 Roberto Tapia-Conyer 7 1 University of Guadalajara, Health Sciences University Center, Guadalajara, Jalisco, Mexico; 2 Carlos Slim Foundation, Mexico City, Mexico; 3 Coordination of Gynecological and Perinatal Endocrinology, National Institute of Perinatology, Mexico City, Mexico; 4 Maternal and Childhood Research Center (CIMIGEN), Mexico City, Mexico; 5 Ministry of Health of the State of Guanajuato, Guanajuato, Mexico; 6 Ministry of Health of the State of Hidalgo, Pachuca, Hidalgo, Mexico; 7 National Autonomous University of Mexico, School of Medicine, Mexico City, Mexico Correspondence: Luis Alberto Martinez-Juarez, Carlos Slim Foundation, Lago Zurich 245, Presa Falcon Building (Floor 20), Miguel Hidalgo, Mexico City, 11529, Mexico, Tel +52 55 53 39 17 70, Fax +52 55 53 39 17 70, Email Purpose: Few pregnant women in low-resource settings are screened for gestational diabetes mellitus (GDM) using the gold standard oral glucose tolerance test (OGTT). This study compared capillary blood glucose testing with 2-h plasma glucose measurements obtained using the 75-g OGTT to screen for GDM at primary healthcare clinics in Mexico. Patients and Methods: Pregnant women who participated in a previous prospective multicenter longitudinal cohort study and who had not been previously diagnosed with diabetes were included. Participants were evaluated using the plasmatic 2-h 75-g OGTT with simultaneous capillary blood glucose measurements using a glucometer. The study endpoint was the comparability of the glucometer results to the gold standard OGTT when collected simultaneously. Sensitivity, specificity, and area under the curve of the glucose measurements obtained for capillary blood compared with venous plasma (gold standard) were calculated to determine diagnostic accuracy. Results: The study included 947 pregnant women who had simultaneous glucose measurements available (blood capillary [glucometer] and venous blood OGTT). Overall, capillary blood glucose testing was very sensitive (89.47%); the specificity was 66.58% and the area under the curve (95% confidence interval) was 0.78 (0.74– 0.81). The sensitivity, specificity and area under the curve of each capillary measurement were: 89.47%, 66.58% and 0.78 (0.74– 0.82) for the fasting measurement, 91.53%, 93.24% and 0.92 (0.88– 0.96) for the one-hour measurement, and 89.80%, 93.32%, 0.91 (0.87– 0.95) for the second-hour measurement, respectively. No adverse events were reported. Conclusion: Capillary OGTT is a valid alternative to the gold standard OGTT for screening of GDM in low-resource situations or in situations where there are other limitations to performing the OGTT as part of primary healthcare services. Keywords: capillary blood glucose, gestational diabetes mellitus, low-resource, Mexico, oral glucose tolerance test, screening Gestational diabetes mellitus (GDM) is a condition diagnosed during pregnancy that was not clearly overt diabetes prior to gestation. 1 GDM is a neglected risk to the health of both mothers and children and can lead to numerous pregnancy-related complications including babies with a larger birth weight, high blood pressure, and obstructed labor. 2 Approximately half of women who experience GDM subsequently develop type 2 diabetes mellitus in the 5–10 years after their baby is delivered. 2 The estimated global prevalence of GDM in 2021 was between 4.3% and 38.1%. 3 The prevalence for North America and the Caribbean is reported to be 20.7%, 4 and in Mexico, while data are insufficient to determine the national prevalence of GDM, it is estimated to be between 10% and 12%. 5,6 Screening and diagnostic strategies for GDM have been a focus of international debate. 7,8 Currently, the 75-g oral glucose tolerance test (OGTT) is considered the gold standard for diagnosing GDM. The American Diabetes Association (ADA) recommends OGTT with three plasma glucose measurements (fastin -Abstract Truncated-